DDInter1491 DDInter782
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Pomalidomide {u} (Compound) binds {v} (Gene) TNF
Pomalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Pomalidomide (Compound) resembles Lenalidomide (Compound)
Pomalidomide (Compound) binds TNF (Gene)
Pomalidomide (Compound) causes Dermatitis (Side Effect)